XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
cSCC is one of the most common cancers in the U.S. and globally
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Subscribe To Our Newsletter & Stay Updated
